Product
HER-2/neu Peptide Vaccine
1 clinical trial
4 indications
Indication
HER2/Neu PositiveIndication
HLA-A2 Positive Cells PresentIndication
Breast CancerIndication
Ovarian CancerClinical trial
Phase I/II Study of Combination Immunotherapy for the Generation of HER-2/Neu (HER2) Specific Cytotoxic T Cells (CTL) in VivoStatus: Completed, Estimated PCD: 2021-03-31